Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and PLCG2. The rate of resistance and clonal composition of PD are incompletely characterized. We report on CLL patients treate...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Ahn, Inhye E., Underbayev, Chingiz, Albitar, Adam, Herman, Sarah E. M., Tian, Xin, Maric, Irina, Arthur, Diane C., Wake, Laura, Pittaluga, Stefania, Yuan, Constance M., Stetler-Stevenson, Maryalice, Soto, Susan, Valdez, Janet, Nierman, Pia, Lotter, Jennifer, Xi, Liqiang, Raffeld, Mark, Farooqui, Mohammed, Albitar, Maher, Wiestner, Adrian
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2017
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356450/
https://ncbi.nlm.nih.gov/pubmed/28049639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-719294
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi